Company Interview / Cyclopharm breathing in new US deal

James McBrayer of Cyclopharm (ASX:CYC) shares that the company has secured a five-year agreement with the US Veterans Health Administration. This deal signifies a notable expansion in the US federal healthcare system, showcasing the importance of Cyclopharm's (ASX:CYC) technology.

James notes uncertainty in the US market but views the contract as a positive sign for business. The focus of the deal is on patient consumables related to a pharmaceutical drug delivery system, crucial for Cyclopharm's revenue.

Globally, Technegas technology is used for diagnosing conditions like COPD and asthma. Improved imaging and AI enhance its applications. James mentions a study that uses Technegas to predict post-lung transplant recovery time. Cyclopharm eyes more installations, potentially increasing their market presence.